Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PTG-630
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : National Eye Institute
Deal Size : $0.3 million
Deal Type : Funding
Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy
Details : Praetego's NEI grant expands PTG-630 to a third indication and builds upon promising findings in both Alzheimer's disease and diabetic peripheral neuropathy. PTG-630 has demonstrated remarkable potency as an AGE inhibitor.
Brand Name : PTG-630
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 01, 2023
Lead Product(s) : PTG-630
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : National Eye Institute
Deal Size : $0.3 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?